2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1573-1588

  Eberhardt, Wilfried E E ^a   De Ruysscher, Dirk ^b   Weder, Walter ^c   Le Péchoux, Cecile ^d   De Leyn, Paul ^e   Hoffmann, H ^f   Westeel, Virginie ^g,af   Stahel, Rolf ^c   Felip, Enriqueta ^h   Peters, Solange ⁱ   Kerr, Keith ^j   Besse, Benjamin ^d   Vansteenkiste, Johan ^e   Edelman, Martin ^k   Mok, Tony ^l   O'Byrne, Ken ^m   Novello, Silvia ⁿ   Bubendorf, Lukas ^o   Marchetti, Antonio ^p   Baas, Paul ^q   Reck, Martin ^r   Syrigos, Konstantinos ^s   Paz Ares, Luis ^t   Smit, Egbert F ^u   Meldgaard, Peter ^v   Adjei, Alex ^w   Nicolson, Marianne ^x   Crinò, Lucio ^y   Van Schil, Paul ^z   Senan, Suresh ^u   Faivre Finn, Corinne ^aa   Rocco, Gaetano ^ab   Veronesi, Giulia ^ac   Douillard, Jean Yves ^ad   Lim, Eric ^ae   Dooms, Christophe ^e   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL OF BESANÇON   (France)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY OF ABERDEEN   (United Kingdom)

^k UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^l CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^m ST JAMES S HOSPITAL   (Ireland)

ⁿ SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p UNIVERSITY OF CHIETI   (Italy)

^q ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^r KRANKENHAUS GROSSHANSDORF   (Germany)

^s First Department of Thoracic Surgery   (Greece)

^t HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^u VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^v AARHUS UNIVERSITY HOSPITAL   (Denmark)

^w ROSWELL PARK CANCER INSTITUTE   (United States)

^x ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^y SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^z ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^aa CHRISTIE HOSPITAL   (United Kingdom)

^ab NATIONAL CANCER INSTITUTE   (Italy)

^ac EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ad Centre Régional Hospitalier Metz Thionville   (France)

^ae ROYAL BROMPTON HOSPITAL   (United Kingdom)

^af UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

ESMO; Locally advanced; Non small cell lung cancer; Recommendations; Stage III

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; ETOPOSIDE; GEFITINIB; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; VINCA ALKALOID; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADVANCED CANCER; AGE; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; ENDOBRONCHIAL ULTRASONOGRAPHY; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LUNG LOBECTOMY; LUNG RESECTION; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MEDIASTINUM LYMPH NODE; MINIMALLY INVASIVE PROCEDURE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; SKULL IRRADIATION; SMOKING CESSATION; SURGICAL MORTALITY; TRANSBRONCHIAL ASPIRATION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ANALOGS AND DERIVATIVES; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EUROPE; LUNG; LUNG NEOPLASMS; LYMPH NODE; MEDIASTINUM; MEDICAL SOCIETY; MULTIMODAL IMAGING; PATHOLOGY; PRACTICE GUIDELINE; RADIOGRAPHY; SCINTISCANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHOSCOPY; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE MANAGEMENT; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; ETOPOSIDE; EUROPE; HUMANS; LUNG; LUNG NEOPLASMS; LYMPH NODES; MEDIASTINUM; MULTIMODAL IMAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 84941599354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv187     Document Type: Article

References (112)

1. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
2. Vansteenkiste J, Crinò L, Dooms C et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014; 25: 1462-1474.
3. Besse B, Adjei A, Baas P et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014; 25: 1475-1484.
4. Kerr KM, Bubendorf L, Edelman MJ et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681-1690.
5. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
6. De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007; 29: 995-1002.
7. Fischer B, Lassen U, Mortensen J et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009; 361: 32-39.
8. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
9. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375: 1267-1277.
10. De Ruysscher D, Faivre-Finn C, Nestle U et al. European Organization for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010; 28: 5301-5310.
11. Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999; 45: 1143-1149.
12. Gaspar LE, Chansky K, Albain KS et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005; 23: 2955-2961.
13. De Leyn P, Vansteenkiste J, Lievens Y et al. Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer. J Thorac Oncol 2009; 4: 62-68.
14. Decaluwé H, De Leyn P, Vansteenkiste J et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009; 36: 433-439.
15. Brunelli A, Charloux A, Bolliger CT et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17-41.
16. Shi W, Zhang W, Sun H, Shao Y. Sleeve lobectomy versus pneumonectomy for non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2012; 10: 265.
17. Vansteenkiste J, De Ruysscher D, Eberhardt WE et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi89-vi98.
18. Lüchtenborg M, Riaz SP, Coupland VH et al. High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol 2013; 31: 3141-3146.
19. Ohri N, Shen Z, Dicker AP et al. Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013; 105: 387-393.
20. Rusch VW, Giroux DJ, Kraut MJ et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472-483.
21. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
22. Van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99: 442-450.
23. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
24. Curran WJ, Jr, Paulus R, Langer CJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103: 1452-1460.
25. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
26. Mauguen A, Pignon JP, Burdett S et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol 2013; 14: 619-626.
27. Harris JP, Murphy JD, Hanlon AL et al. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 88: 872-884.
28. Robinson LA, Ruckdeschel JC, Wagner H, Jr et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(Suppl 3): 243S-265S.
29. Rami-Porta R, Wittekind C, Goldstraw P, International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49: 25-33.
30. Hillinger S, Weder W. Extended surgical resection in stage III non-small cell lung cancer. Front Radiat Ther Oncol 2010; 42: 115-121.
31. Lequaglie C, Conti B, Brega Massone PP, Giudice G. Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patients after long-term follow-up. Eur J Cardiothorac Surg 2003; 23: 229-232.
32. Rusch VW. Management of Pancoast tumours. Lancet Oncol 2006; 7: 997-1005.
33. van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected nonsmall-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-1393.
34. Herder GJ, Kramer H, Hoekstra OS et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006; 24: 1800-1806.
35. De Leyn P, Dooms C, Kuzdzal J et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2014; 45: 787-798.
36. Gould MK, Kuschner WG, Rydzak CE et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139: 879-892.
37. Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 2005; 80: 1207-1213; discussion 1213-1214.
38. Dong X, Qiu X, Liu Q, Jia J. Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis. Ann Thorac Surg 2013; 96: 1502-1507.
39. Micames CG, McCrory DC, Pavey DA et al. Endoscopic ultrasound-guided fineneedle aspiration for non-small cell lung cancer staging*: a systematic review and meta-analysis. Chest 2007; 131: 539-548.
40. Annema JT, van Meerbeeck JP, Rintoul RC et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 2010; 304: 2245-2252.
41. Zhang R, Ying K, Shi L et al. Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis. Eur J Cancer 2013; 49: 1860-1867.
42. Pöttgen C, Eberhardt W, Grannass A et al. Prophylactic cranial irradiation in operable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 2007; 25: 4987-4992.
43. Cox JD, Scott CB, Byhardt RW et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999; 43: 505-509.
44. Kim SY, Kim JS, Park HS et al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci 2005; 20: 121-126.
45. Hendriks LE, Bootsma GP, de Ruysscher DK et al. Screening for brain metastases in patients with stage III non-small cell lung cancer: is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain? Lung Cancer 2013; 80: 293-297.
46. Marks LB, Yorke ED, Jackson A et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76(Suppl 3): S10-S19.
47. Marks LB, Bentzen SM, Deasy JO et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010; 76(Suppl 3): S70-S76.
48. De Ruysscher D, Botterweck A, Dirx M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102.
49. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
50. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 357-364.
51. Colinet B, Jacot W, Bertrand D et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93: 1098-1105.
52. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
53. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
54. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; 16: 672-681.
55. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
56. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24: 2998-3006.
57. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol 2007; 25: 5506-5518.
58. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343: 1217-1222.
59. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-smallcell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
60. Rosell R, Gómez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with nonsmall-cell lung cancer. N Engl J Med 1994; 330: 153-158.
61. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
62. Rosell R, Gómez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7-14.
63. Scagliotti GV, Pastorino U, Vansteenkiste JF et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30: 172-178.
64. Lorent N, De Leyn P, Lievens Y et al. Long-term survival of surgically staged IIIAN2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004; 15: 1645-1653.
65. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16: 622-634.
66. Eberhardt WE, Gauler TC, LePechoux C et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer 2013; 82: 83-89.
67. Albain KS, Crowley JJ, Turrisi AT, III et al. Concurrent cisplatin etoposide, and chest radiotherapy in pathologic stage IIIB non-small cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-3460.
68. Stamatis G, Eberhardt W, Stüben G et al. Preoperative chemoradiotherapy and surgery for selected non-small-cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999; 68: 1144-1149.
69. Stupp R, Mayer M, Kann R et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 2009; 10: 785-793.
70. Friedel G, Budach W, Dippon J et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010; 28: 942-948.
71. Kim AW, Liptay MJ, Bonomi P et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg 2011; 92: 233-241; discussion 241-243.
72. Seder CW, Allen MS, Cassivi SD et al. Stage IIIA non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg 2013; 95: 1708-1716.
73. Thomas M, Rube C, Hoffknecht P et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomized trial in stage III non-small cell lung cancer. Lancet Oncol 2008; 9: 636-648.
74. Katakami N, Tada H, Mitsudomi T et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 2012; 118: 6126-6135.
75. Weder W, Collaud S, Eberhardt WE et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010; 139: 1424-1430.
76. Kris MG, Pisters KM, Ginsberg RJ et al. Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Lung Cancer 1995; 12(Suppl. 1): S47-S57.
77. Eichhorn F, Storz K, Hoffmann H et al. Sleeve pneumonectomy for central nonsmall cell lung cancer: indications, complications, and survival. Ann Thorac Surg 2013; 96: 253-258.
78. Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg 2012; 143: 55-63.
79. Pless M, Stupp R, RIs H-B. Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): a randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). J Clin Oncol 2013; 31(suppl): abstr 7503.
80. Pless M, Stupp R, Ris H et al. Final results of the SAKK 16/00 trial: a randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small cell lung cancer (NSCLC). Ann Oncol 2014; 25(suppl. 4): iv417.
81. Rusch VW, Giroux DJ, Kraut MJ et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25: 313-318.
82. Eberhardt W, Gauler T, Pöttgen C et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with operable (OP+) stage IIIA (N2)/selected IIIb non-small cell lung cancer (NSCLC) following induction chemotherapy and concurrent CRTx (ESPATUE). J Clin Oncol 2014; 32(5s suppl): abstr 7510.
83. Bradley JD, Paulus R, Komaki R et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015; 16: 187-199.
84. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 study. J Clin Oncol 2005; 23: 5910-5917.
85. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
86. O'Rourke N, Roqué I Figuls M, Farré Barnabo N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010; 6: CD002140.
87. Wang L, Wu S, Ou G et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012; 77: 89-96.
88. Garrido P, Rosell R, Arellano A et al. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer 2013; 81: 84-90.
89. Belderbos J, Uitterhoeve L, van Zandwijk N et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007; 43: 114-121.
90. Reymen B, van Baardwijk A, Wanders R et al. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemoradiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiother Oncol 2014; 110: 482-487.
91. Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013; 31: 1029-1038.
92. Mauguen A, Le Péchoux C, Saunders MI et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 2788-2797.
93. Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350: 161-165.
94. Gore EM, Bae K, Wong SJ et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of Radiation Therapy Oncology Group study RTOG 0214. J Clin Oncol 2011; 29: 272-278.
95. Blanke C, Ansari R, Mantravadi R et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13: 1425-1429.
96. Clamon G, Herndon J, Cooper R et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.
97. Groen HJ, van der Leest AH, Fokkema E et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small cell lung cancer: a multicenter phase III study. Ann Oncol 2004; 15: 427-432.
98. Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13: 671-678.
99. Hanna N, Neubauer M, Yiannoutsos C et al. Phase III study of cisplatin etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-5760.
100. Vokes EE, Herndon JE, II, Kelley MJ et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-1704.
101. Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 2000; 46: 516-517.
102. Belderbos JS, Kepka L, Spring Kong FM et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008; 72: 335-342.
103. Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol 2010; 20: 171-177.
104. Liu HH, Balter P, Tutt T et al. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 2007; 68: 531-540.
105. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25: 1553-1561.
106. Berry MF, Worni M, Pietrobon R et al. Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. J Thorac Oncol 2013; 8: 744-752.
107. Kelly K, Chansky K, Gaspar LE et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-2456.
108. Goss GD, O'Callaghan C, Lorimer I et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013; 31: 3320-3326.
109. Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2013; 2: 208.
110. Westeel V, Lebitasy MP, Mercier M et al. IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer. Rev Mal Respir 2007; 24: 645-652.
111. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569.
112. Khuri FR, Kim ES, Lee JJ et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001; 10: 823-829.